药物类型 小分子化药 |
别名 Amlodipine besilate/irbesartan、Amlodipine/irbesartan、Aprovasc + [6] |
作用机制 AT1R拮抗剂(血管紧张素II-1型受体拮抗剂)、VDCCs阻滞剂(电压门控性钙通道复合体阻滞剂) |
治疗领域 |
在研适应症 |
非在研适应症 |
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 哥伦比亚 (2012-06-29), |
最高研发阶段(中国)临床3期 |
特殊审评- |
分子式C26H31ClN2O8S |
InChIKeyZPBWCRDSRKPIDG-UHFFFAOYSA-N |
CAS号111470-99-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
适应症 | 国家/地区 | 公司 | 日期 |
---|---|---|---|
高血压 | 哥伦比亚 | 2012-06-29 |
临床3期 | - | 290 | 齋選膚遞簾範鬱範簾淵(蓋糧醖築獵鏇獵襯範襯) = 觸構遞糧積窪構糧窪鬱 願範簾鏇簾衊淵鬱選遞 (願顧構鑰憲鏇積蓋憲選, 1.0) | 积极 | 2012-08-01 | ||
临床3期 | 325 | (獵鏇憲憲窪遞網廠窪範) = Treatment-emergent adverse events were experienced by 10.5% of I300/A5-treated patients and 6.6% of I300-treated patients during the second 5-week period. Three serious adverse events were reported; 2 with monotherapy (1 with I150 and 1 with I300) and 1 with fixed-dose combination I300/A5. All patients affected by serious adverse events made a full recovery. 淵壓鹹窪糧膚範鹽鏇襯 (憲鬱餘獵觸鏇醖窪顧廠 ) | 积极 | 2012-08-01 |